0.30). Group FLD patients had a longer length of hospital stay (P ϭ 0.030). Patients in Group R had a significantly infrequent rate of hypertension but a frequent rate of hypotension (P Ͻ 0.01). The urinary cortisol excretion was larger in Group FLD patients (P Ͻ 0.0005), and urine flow was smaller (P Ͻ 0.0005). Remifentanil was associated with a propofol dose reduction (P ϭ 0.0005) and a concomitant higher bispectral index (P ϭ 0.032). Three Group FLD patients, but none in groups FMD and R, had postoperative myocardial infarctions (P ϭ 0.032). Remifentanil has larger drug acquisition costs but does not increase the total hospital costs associated with cardiac surgery.
(Anesth Analg 2002;95:805-12) G oals of anesthesia for coronary artery bypass graft (CABG) surgery include hypnosis, hemodynamic stability, and neurohumoral stress ablation (1) and may include early tracheal extubation (2, 3) . Fast-track cardiac surgery is partly dependent on smaller-dose opioid regimens (2, 3) , and although these may be associated with increased hemodynamic responses during surgery, there does not appear to be an increased risk of complications (3) .
Remifentanil is a satisfactory adjunct during cardiac surgery (4 -8) , but it is uncertain whether it should replace other established opioids. Given its unique pharmacokinetic profile, large-dose remifentanil can be used to ablate stress responses and should allow faster recovery after cardiac surgery. This approach may reduce perioperative complications and length of stay. Nevertheless, remifentanil is a relatively expensive drug, and it is unclear whether the additional cost of acquisition can be outweighed by savings in total hospital costs. We therefore studied the costs and outcomes of a remifentanil regimen compared with two separate fentanyl regimens for cardiac surgery.
Methods
After Ethics Committee approval, we approached all consecutive eligible elective CABG surgical patients aged Ͻ75 yr and obtained written, informed consent. Patients were excluded if they were Ͼ100 kg, were allergic to trial medications, were considered at very high risk (defined as a Tu score of Ͼ9) (9) , had uncontrolled hyper-or hypotension, had congestive cardiac failure or an ejection fraction of Ͻ25%, had atrioventricular or left bundle branch block detected on their preoperative electrocardiogram (ECG), or had a pacemaker in situ.
This was a prospective, randomized, doubleblinded trial of three active treatment groups:
1. Group R: remifentanil infusion at 0.83 g · kg Ϫ1 · min Ϫ1 . 2. Group FLD: fentanyl bolus, small dose, at 12 g/kg. 3. Group FMD: fentanyl bolus, moderate dose, at 24 g/kg.
Patients were stratified before randomization into low risk (Tu score Ͻ2) (9) and high risk (Tu score 2-6) to maximize equality of groups. The clinical trials unit of our hospital pharmacy department prepared each of the following solutions according to the randomization code (table of random numbers) and maintained blinding of study drug preparations:
1. Group R: saline (placebo) in 20-mL syringes for the bolus and remifentanil 5 mg in 50-mL syringes (100 g/mL) for the infusion. 2. Group FLD: fentanyl 500 g in 20-mL syringes for the bolus and saline (placebo) in 50-mL syringes for the infusion. 3. Group FMD: fentanyl 1000 g in 20-mL syringes for the bolus and saline (placebo) in 50-mL syringes for the infusion.
The patient's usual medications were continued until the time of operation. All patients received a standard premedication of oral temazepam 10 mg, IM morphine 5 mg, and oxygen delivered via face mask at 5 L/min. Patient monitoring consisted of five-lead ECG, pulse oximetry, capnography, invasive arterial pressure, and pulmonary artery pressure. Correct ECG ST segment monitoring was confirmed (with definition of isoelectric line and J point). Intravascular catheters were inserted with local anesthesia before induction by using IV midazolam in 0.5-mg increments.
Bispectral index (BIS ® ; Aspect Medical Systems Inc., Natick, MA) electrodes were applied according to the manufacturer's instructions, and BIS ® A1050 monitoring commenced. All patients had an identical induction technique commencing with a propofol infusion at 8 mg · kg Ϫ1 · h Ϫ1 until loss of the eyelash reflex. An intravenous trial drug bolus was then administered at 0.32 mL/kg via the 20-mL syringes, and the trial drug infusion immediately commenced at 0.5 mL · kg Ϫ1 · h Ϫ1 by using the 50-mL syringes prepared by the pharmacy. Thus, the patients received one of the following: fentanyl 8 g/kg (Group FLD), fentanyl 16 g/kg (Group FMD), or remifentanil 0.83 g · kg Ϫ1 · min Ϫ1 (Group R). Muscle relaxation and tracheal intubation followed 3 min after IV pancuronium 0.12 mg/kg. The propofol infusion was reduced to 5 mg · kg Ϫ1 · h Ϫ1 immediately after tracheal intubation. A further bolus of trial drug, 0.16 mL/kg, was given before sternotomy. Thus, patients in Groups FLD and FMD had received their complete allocated trial medication at this stage, with those in Group R continuing to receive remifentanil at 0.83 g · kg Ϫ1 · min Ϫ1 .
Further propofol and study drug dosage adjustments were standardized by protocol, according to adverse hemodynamic responses and BIS ® measurements. In general, this consisted of 1. a bolus of propofol and trial drug and increased propofol and trial drug infusion rates if signs of "light" anesthesia (hypertension, tachycardia, or BIS ® Ͼ60) 2. or reduced propofol and trial drug infusion rates if signs of "deep" anesthesia (hypotension or BIS ® Ͻ40).
All patients had a nitroglycerin (NTG) infusion commenced after the induction of anesthesia at 0.2 g · kg Ϫ1 · min Ϫ1 (except during cardiopulmonary bypass [CPB]). A dose of NTG 0.4 g · kg Ϫ1 · min Ϫ1 was used after removal of the aortic cross-clamp.
Patients' lungs were ventilated with a tidal volume of 10 mL/kg, adjusting the respiratory rate to an endtidal carbon dioxide of 32-34 mm Hg. CPB was standardized by using a crystalloid/colloid prime, membrane oxygenator, moderate hypothermia (32°C-34°C), and alpha-stat pH management.
Postoperative analgesia consisted of IV ketorolac 10 mg and morphine 1-2 mg/h. Neuromuscular block was reversed. Propofol sedation, if required, was commenced at 0.5 mg · kg Ϫ1 · h Ϫ1 . Patients remained intubated and mechanically ventilated for transfer to the intensive care unit (ICU). Patients were weaned from mechanical ventilation as soon as they responded to verbal stimuli and were normothermic, hemodynamic stability had been established, and blood loss was satisfactory (Ͻl00 mL/h). This adhered to standard fast-track protocols (2, 3) . Tracheal extubation occurred when the patient was awake and cooperative, with a respiratory rate between 10 and 20 breaths/min, and had satisfactory arterial blood gas analyses.
Hemodynamic variables were measured at set time points. Cardiac output was measured with the thermodilution method (10 mL of room temperature saline at end-expiration, in triplicate). The total amount of intraoperative vasoactive drugs and cardiac pacing requirements were recorded. The patient's intraoperative urine volume was recorded for calculation of flow and cortisol excretion.
Continuous three-lead (II, aVL, V5) automated ST segment analysis was used to detect intraoperative myocardial ischemia. Ischemia was defined as ST segment depression Ͼ1 mm or elevation Ͼ2 mm at 60 ms after the J point, persisting for at least 2 min; each new episode was confirmed with a real-time visual check by the investigator. Transesophageal echocardiography was not routinely used. A 12-lead ECG was performed on admission to the ICU and daily for 3 days after surgery. Blood was taken at 6 and 36 h for troponin I levels. Acute myocardial infarction was diagnosed if new Q waves appeared in at least two adjacent ECG leads, as determined by a blinded cardiologist.
Sedative and analgesic requirements were documented for the first 24 h after ICU admission. Time to tracheal extubation (from ICU admission) and "fitness for discharge" from ICU were recorded. (ICU "fit for discharge" criteria were 1) awake and cooperative [Glasgow Coma Scale Ͼ12]; 2) extubated, ventilation satisfactory [respiratory rate Ͻ30 breaths/min, pH Ͼ7.30]; 3) temperature Ͼ36.0°C; 4) stable hemodynamics; 5) no life-threatening arrhythmias; 6) blood loss Ͻ200 mL/4 h; and 7) inotropes: dopamine Ͻ5 g · kg Ϫ1 · min Ϫ1 [or equivalent]).
Cost analyses were performed by a health economist (JW), by using a data collection form designed to capture resource use in the operating theater (OT) and cardiothoracic ICU (10) . Intraoperative resource use data were recorded, including the total procedure time, drugs, and doses administered. ICU resource use included recovery times, length of stay, and drug administrations. In addition, the time the patient was "fit for discharge" was recorded to take account of any exit blocks between ICU and the general ward.
The total hospital costs for 51 patients were extracted from the hospital's clinical costing system according to the following cost categories: OT, ICU, ward nursing, pharmacy, imaging, pathology, and an "other" category, which included allied health and medical. For 23 pre-July 1999 patients, clinical costing data could not be extracted because the hospital's system was not operating. For these patients, utilization data were extracted from the admission transfer discharge system, and the costs were estimated by using mean unit costs from the subsequent patients. Cost data were available from 76 patients.
The two sources of costing and resource utilization data (data collection form and hospital clinical costing data) enabled estimation of costing data in the areas where the trial anesthetic drug regimen may affect perioperative resource use, particularly the OT and ICU. A modeled OT and ICU cost was determined by substituting the relevant recorded activity from the hospital's information system with length of stay and OT drug administration from the data collection form. For pharmacy costs, the actual drugs and amounts administered were recorded for all relevant drugs. Acquisition drug costs provided by the hospital's pharmacy department were used to calculate OT drug costs. All modeled costs were substituted for data extracted from the clinical costing system. Total cost thus included clinical costing data for ward, pharmacy, pathology, imaging, and other costs and modeled costs for OT and ICU for 76 patients. These modeled costs provide a more precise total cost based on a more accurate recording of resource utilization in the OT and ICU. Hospital length of stay included the day of surgery. All costs are presented in Australian dollars (1999 -2000) , where AUS$1 Ϸ US$0.55.
A preliminary estimate of sample size of 25 patients per group was based on an expected 30% reduction in time to tracheal extubation after surgery, on the basis of our unit's current practice (mean difference 10 vs 7 h, sd 4 h; Type I error of 0.05; Type II error of 0.20). The primary end-points were time to tracheal extubation and length of hospital stay.
Normally distributed data were analyzed by using general linear models and are presented as mean (sd). The Tu score (9) and baseline hemodynamic variables were included as covariates in the analysis of hemodynamic data. Nonnormally distributed data were analyzed with Kruskal-Wallis analysis of variance and are presented as median (interquartile range); post hoc testing was with Student's t-tests or Mann-Whitney U-tests. Associations were compared by using the Spearman rank order correlation, rho. Proportions were analyzed by 2 and Yates' correction or Fisher's exact test and are presented as n (%). A P value Ͻ0.01 was considered significant for the analysis of the multiple hemodynamic variables. The Hochberg procedure was used for post hoc comparisons (11) . All statistical analyses were performed with SPSS for Windows Version 9.0 (SPSS, Inc., Chicago, IL).
Results
Eighty-seven patients were enrolled in this study, with subsequent exclusion of 10 patients (1 patient withdrew consent before surgery, 2 patients had their surgery deferred, and 7 patients failed to receive their allotted study medication). The groups were well matched for relevant perioperative factors (Table 1) . No patient reported intraoperative awareness after direct questioning. One patient in Group FLD had a postoperative stroke. There was a significant difference in the time to tracheal extubation, and patients in Group FLD had a longer length of hospital stay ( Table  2) .
Exploration of the costing data revealed three highcost outliers, with total costs of $53,369, $100,726, and $205,411. The first patient had similar costs to other patients for OT and ICU but had a ward length of stay of 63 days. This patient, in Group R, experienced a deep sternal wound infection. A second patient had an ICU length of stay of 16 days and a ward length of stay of 93 days; this patient, from Group FLD, had a myocardial infarction in the ICU.
Mean and median total variable costs are reported for the three groups of patients, with the high-cost outlier cases included, in Table 3 . These findings show that, although not statistically significant, Group FLD had a higher mean total cost compared with the other two groups, with a mean cost difference of approximately $1000. Further analyses of mean cost data are reported both with and without high-cost outliers (Tables 3 and 4).
Patients in Group R had a significantly smaller rate of hypertension but a larger rate of hypotension than those in Groups FLD and FMD (Tables 5 and 6 ). There was a concomitant increased vasoconstrictor requirement (P Ͻ 0.0005) but no difference in inotropic support (P ϭ 0.96) or cardiac pacing requirement (P ϭ 0.76). Urinary cortisol excretion was significantly smaller and urine flow was larger in Group R (Table  6 ). This occurred despite similar amounts of intraoperative fluid administration (P ϭ 0.39).
The groups had similar rates of intraoperative myocardial ischemia, but patients in Group FLD had a more frequent rate of myocardial infarction (Table 6 ). There was a correlation between cardiac troponin I at 6 and 24 h and the duration of intraoperative myocardial ischemia (as detected by ST segment changes); rho ϭ 0.26 (P ϭ 0.029) and 0.55 (P Ͻ 0.0005), respectively.
Remifentanil was associated with a reduction in the need to give additional opioids (P ϭ 0.0005) and significantly reduced anesthetic (propofol) requirements (Table 7) . BIS ® scores were higher in Group R (P ϭ 0.032). There were no differences in postoperative analgesic (P ϭ 0.24) or sedative requirements (P ϭ 0.21).
Discussion
In this double-blinded, randomized, controlled trial we studied the cost effectiveness of remifentanil compared with two typical fentanyl regimens in patients Values are median (interquartile range). Group R ϭ remifentanil 0.83 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ; Group FLD ϭ fentanyl 12 g/kg; Group FMD ϭ fentanyl 24 g/kg; ICU ϭ intensive care unit; LOS ϭ length of stay. a Post hoc testing: R versus FLD, P ϭ 0.14; R versus FMD, P ϭ 0.30; FLD versus FMD, P ϭ 0.008. b Adjusted for ventricular function and Tu score (9), using general linear models of transformed data: R versus FLD, P ϭ 0.026; R versus FMD, P ϭ 0.86; FLD versus FMD, P ϭ 0.057. having CABG surgery with a propofol-based technique aiming for early tracheal extubation. The study population was typical of current cardiac surgical practice, and BIS ® monitoring was used to titrate propofol in all patients.
Patients in Group FLD were able to be extubated earlier than those in Group FMD, with patients in Group R being intermediate. Because there may be a relationship between the neurohumoral stress response and postoperative myocardial ischemia (1), large-dose opioid techniques have been the preferred technique in many centers. Our study suggests that remifentanil can provide this effect without prolonging recovery times. In contradistinction, small-dose fentanyl, although associated with shorter tracheal extubation times, did not reduce ICU or hospital length of stay.
We found that remifentanil provided better mitigation against hypertension than either moderate-or small-dose fentanyl, although it contributed to more episodes of hypotension requiring vasoconstrictor use. The larger dose of fentanyl afforded some degree Values are mean (sd) or median (interquartile range). Group R ϭ remifentanil 0.83 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ; Group FLD ϭ fentanyl 12 g/kg; Group FMD ϭ fentanyl 24 g/kg. OT ϭ operating theater; ICU ϭ intensive care unit; LOS ϭ length of stay; FFD ϭ fit for discharge. a R versus FLD, P ϭ 0.004; R versus FMD, P ϭ 0.39; FLD versus FMD, P ϭ 0.043. Values are mean (sd). Group R ϭ remifentanil 0.83 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ; Group FLD ϭ fentanyl 12 g/kg; Group FMD ϭ fentanyl 24 g/kg. CPB ϭ cardiopulmonary bypass; ICU ϭ intensive care unit; PCWP ϭ pulmonary capillary wedge pressure; BP ϭ blood pressure. c Repeated-measures general linear models (post hoc testing: a R versus FLD, P Ͻ 0.01; b FMD versus R and FMD, P Ͻ 0.01).
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of protection when compared with small-dose fentanyl. Other markers of cardiac performance, particularly the need for cardiac pacing or inotropic support, were not affected. There was a highly significant reduction in cortisol excretion in Group R patients (and to a lesser extent those in Group FMD) compared with the small-dose fentanyl technique, suggesting greater neurohumoral stress ablation with remifentanil. A preliminary report 1 found that remifentanil blunted catecholamine secretion in CABG patients. This mechanism may explain the increased urine flow rates seen with remifentanil. In our study, both fentanyl groups required significantly more "top-up" opioid doses to treat light anesthesia or hemodynamic hyperresponsiveness. There were in fact lower average BIS ® scores in Group FLD patients, and this is consistent with the additional hypnotic required to maintain hemodynamic stability.
Our findings are generally consistent with those of Howie et al. (6) , who found similar times to tracheal extubation with remifentanil and moderate-dose (approximately 22 g/kg) fentanyl by using an isoflurane-based technique. They reported fewer hemodynamic disturbances with remifentanil but could 1 Values are mean (sd), median (interquartile range), or n (%). Group R ϭ remifentanil 0.83 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ; Group FLD ϭ fentanyl 12 g/kg; Group FMD ϭ fentanyl 24 g/kg. HR ϭ heart rate; mBP ϭ mean blood pressure. Post hoc testing: a R versus FLD, P ϭ 0.003; R versus FMD, P ϭ 0.005; FLD versus FMD, P ϭ 0.86; b R versus FLD, P ϭ 0.003; R versus FMD, P ϭ 0.012; FLD versus FMD, P ϭ 0.68; c R versus FLD, P ϭ 0.002; R versus FMD, P ϭ 0.001; FLD versus FMD, P ϭ 0.74; d R versus FLD, P ϭ 0.008; R versus FMD, P ϭ 0.06; FLD versus FMD, P ϭ 0.24; e R versus FLD, P Ͻ 0.0005; R versus FMD, P ϭ 0.21; FLD versus FMD, P ϭ 0.001; f R versus FLD, P ϭ 0.086; FLD versus FMD, P ϭ 0.23. Values are mean (sd) or median interquartile range. Group R ϭ remifentanil 0.83 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ; Group FLD ϭ fentanyl 12 g/kg; Group FMD ϭ fentanyl 24 g/kg. CPB ϭ cardiopulmonary bypass. Post hoc testing: a R versus FLD, P ϭ 0.007; R versus FMD, P ϭ 0.006; FLD versus FMD, P ϭ 0.28; b R versus FLD, P Ͻ 0.001; R versus FMD, P ϭ 0.002; FLD versus FMD, P ϭ 0.13; c R versus FLD, P ϭ 0.039; R versus FMD, P ϭ 0.98; FLD versus FMD, P ϭ 0.12. not identify a relative reduction in catecholamine levels in this comparative study, which may be explained by the marked variance in their catecholamine data, suggesting that their study was underpowered for this end-point. In a separate article (7) , their group reported similar resource utilization, but no explicit cost comparisons were performed. They did not include a smaller-dose fentanyl group, so our study provides additional information for those who use such a technique.
There was an apparent increased rate of myocardial infarction in Group FLD, although this was limited to three patients. Cheng et al. (3) found that early tracheal extubation was not associated with any demonstrable increase in postoperative complications.
This study suggest that the higher direct cost of remifentanil may be associated with cost savings as a result of a reduction in ward length of stay, particularly when comparing remifentanil with small-dose fentanyl. No significant difference in mean total variable cost among the three groups suggests that the decision to use remifentanil should not rely solely on the comparatively higher cost of the drug itself. These findings suggest that there may be downstream savings because of a reduction in postoperative general ward length of stay, thus countering the effect of the higher direct drug costs in the perioperative setting. A comparison of actual and "fit for discharge" times in the ICU suggests that there may be some savings to hospitals where ICU "exit blocks" are minimized, although simulation studies suggest that this may not be easily achieved (12) .
Cost comparisons were limited by the sample size of our study. It is interesting to note that Engoren et al. (8) found no statistically significant difference in costs (P ϭ 0.3) when comparing fentanyl, sufentanil, and remifentanil for cardiac surgery, but there appeared to be higher costs with fentanyl (US$7841) compared with remifentanil (US$6286). The decision to use a particular drug regimen is generally based on clinical factors; however, in output-based hospital funding environments, pressure is often applied to clinicians to minimize costs. Further studies incorporating a larger sample size to take resource differences into account may be valuable in influencing these decisions.
We chose to study two doses of fentanyl (12 and 24 g/kg), aiming to represent current cardiac anesthetic practice, in which early tracheal extubation is a goal. It is possible that larger doses may be more effective in modifying the stress response, but they may also lead to a slower recovery profile. We did not find a significant difference in rates of myocardial ischemia; this may be related to the small incidence of this complication, so our study may have been underpowered to provide a reliable comparison, and other monitoring may have been more sensitive. Because we performed statistical tests on multiple end-points, there is an increased likelihood of a Type I error. Our study was not designed to identify smaller differences in some end-points (myocardial ischemia, ICU, and hospital discharge). We therefore urge considered interpretation by the reader and would recommend further investigation to confirm our results.
Conclusions
Remifentanil, when compared with fentanyl (total doses of approximately 15 and 28 g/kg, respectively), did not significantly reduce the duration of tracheal intubation after CABG surgery. However, remifentanil did blunt hypertensive responses and, when compared with fentanyl 15 g/kg, cortisol excretion; this was at the expense of more episodes of hypotension. Larger doses of opioids (remifentanil 0.85 g · kg Ϫ1 · min Ϫ1 or fentanyl 28 g/kg) may be associated with a decreased rate of myocardial infarction.
